AN2 Therapeutics, Inc. (ANTX)

US — Healthcare Sector
Peers: ACLX  ACRV  ANEB  HLVX  MLYS  MOLN  PEPG  PMVP  TYRA  VIGL 

Automate Your Wheel Strategy on ANTX

With Tiblio's Option Bot, you can configure your own wheel strategy including ANTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ANTX
  • Rev/Share 0.0
  • Book/Share 2.4399
  • PB 0.4344
  • Debt/Equity 0.0
  • CurrentRatio 8.6797
  • ROIC -0.6823

 

  • MktCap 31986263.0
  • FreeCF/Share -1.4071
  • PFCF -0.7564
  • PE -0.7024
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.5317

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About AN2 Therapeutics, Inc. (ANTX)

  • IPO Date 2022-03-25
  • Website https://www.an2therapeutics.com
  • Industry Biotechnology
  • CEO Eric E. Easom
  • Employees 22
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.